Movement Alert｜SKB BIO Falls 3.17% in Regular Trading, Innovative Drug Sector Pullback Weighed on Sentiment

Market Focus10-22 10:40

On October 22, SKB BIO fell 3.17% in Regular Trading, trading around HK$459.4, with turnover of HK$80.10 million.

The move aligned with a broader pullback in Hong Kong innovative drug names after several sessions of strength tied to China’s outbound licensing data, with sector sentiment turning more mixed on the day.

Recent market focus had been on official commentary that China’s innovative drug outbound technology licensing reached about $130 billion in the first three quarters, close to the full-year level of last year, which had supported the sector earlier this week. However, on October 22, peer stocks came under pressure, including AKESO falling 7.0%, EVEREST MED falling 5.05%, and INNOVENT BIO falling 4.26%, indicating sector-wide profit-taking and sentiment weakness that also dragged on SKB BIO.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment